Array BioPharma To Present At The Leerink Swann Global Healthcare Conference

 Array BioPharma To Present At The Leerink Swann Global Healthcare Conference

PR Newswire

BOULDER, Colo., Feb. 8, 2013

BOULDER, Colo., Feb. 8, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:
ARRY) today announced that its Chief Executive Officer, Ron Squarer, will
present at the Leerink Swann Healthcare Conference in New York. The public is
welcome to participate in the conference through a webcast on the Array
BioPharma website.


Event:          Leerink Swann Healthcare Conference
Presenter:         Ron Squarer, Chief Executive Officer
Date: Thursday, February 14, 2013
Time:     8:00 a.m. Eastern Time
Location:   The Waldorf Astoria, New York, NY

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery,
development and commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. During 2013, Array expects to make substantial
progress in generating data to inform registration study decisions for our
wholly-owned hematology programs, ARRY-520 and ARRY-614. Array-invented
MEK162 will be tested in a Phase 3 trial in NRAS melanoma which is scheduled
to start in April 2013, as well as BRAF mutant melanoma later in 2013 (with
Novartis). Also, AstraZeneca recently announced a potential start of a Phase 3
trial with Array-invented selumetinib in non-small cell lung cancer during the
second half of 2013. For more information on Array, please go to

CONTACT: Tricia Haugeto
          Array BioPharma Inc.

SOURCE Array BioPharma Inc.
Press spacebar to pause and continue. Press esc to stop.